Gaudium IVF IPO Opens This Week - Here's All You Need To Know

After the muted stock market debut of Fractal Analytics and Aye Finance, the primary market will see another test of investor appetite this week as Gaudium IVF and Women's Health launch their initial public offering (IPO).

Gaudium IVF and Women's Health, an in vitro fertilisation (IVF) and women’s healthcare services provider, operates in the specialised fertility treatment segment. The company offers assisted reproductive solutions and related clinical care and support services.

Gaudium IVF IPO: Key Dates

The Gaudium IVF IPO will open on February 20, 2026, and close on February 24, 2026.

The allotment of shares is expected on February 25, and they are scheduled to list on both the BSE and the NSE on February 27, 2026.

Gaudium IVF IPO: Issue Size, Price Band

Through the issue, the company is offering 20.88 million shares, including a fresh issue of 11.39 million shares and an offer for sale (OFS) of 9.49 million shares.

The company is yet to announce the price band, and hence, the overall size of the issue is not known yet.

Gaudium IVF IPO: Other Details

Sarthi Capital Advisors is the book-running lead manager, and Bigshare Services is acting as the registrar.

The company has reserved up to 50 per cent of the net issue for Qualified Institutional Buyers (QIBs). It will allocate not less than 35 per cent to retail investors, while Non-Institutional Investors (NIIs) will receive not less than 15 per cent of the offering.

Gaudium IVF IPO Objectives

Gaudium IVF and Women's Health plans to utilise the net proceeds from the fresh issue to fund capital expenditure for setting up new IVF centres.

The company will also use a portion of the proceeds to repay or prepay certain outstanding borrowings, and the remaining funds will be allocated for general corporate purposes.

Gaudium IVF Financial Performance

As of the half year ended September 30, 2025 (H1FY26), Gaudium IVF IPO reported total income of Rs 49.75 crore, an Ebitda of Rs 18.95 crore and a profit after tax (PAT) of Rs 12.51 crore.

For the full year FY25, the healthcare company reported a total income of Rs 70.96 crore, up from Rs 48.15 crore in FY24 and Rs 44.26 crore in FY23.

Ebitda for the full year came in at Rs 28.63 crore, up from Rs 19.27 crore in FY24 and Rs 20.07 crore in FY23. PAT stood at Rs 19.13 crore in FY25, up from Rs 10.32 crore in FY24 and Rs 13.53 crore in FY23.

The net worth of Gaudium IVF stood at Rs 58.85 crore as of September 30, 2025, more than doubling from Rs 22.73 crore over the preceding three years.